Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 15 Feb 2016 Planned number of patients changed from 72 to 74 as reported by ClinicalTrials.gov record.
- 13 Jan 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov.